B+
Bull case
25%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
PRTA
ProthenaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-22
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+58.9
Score
AI commentary
The available news set is thin. The stored AP Q2 snapshot reported adjusted loss of $0.32 per share versus a three-analyst estimate of $0.39, but current analyst revisions and a reliable post-release price reaction are unavailable. Recent Form 4 purchases by a 10% owner are disclosed activity, not evidence of trial outcomes. [#SEC-FORM4-2026-10-15] Social, options, short-interest, and employee metrics are unavailable; the zero fields above denote missing data, not neutral readings.
RankAlpha Sentiment Codex - 2026-10-22
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31catalystBristol Myers Squibb decision on PRX019High impact
Prothena said Bristol Myers Squibb's decision on whether to advance PRX019 is expected by year-end 2026; advancement could trigger a $55 million clinical milestone. The payment is contingent, not assured. [#SEC-8K-2026-08-06]
2027-06-30eventTargetTau-1 Phase 2 primary completionHigh impact
Bristol Myers Squibb expects primary completion of its moponetug trial in early Alzheimer's disease in the first half of 2027. Completion is not itself a positive readout; delays or weak results remain material risks. [#SEC-8K-2026-08-06]
2029-12-31catalystPartnered Phase 3 trial executionHigh impact
Roche's prasinezumab PARAISO trial and Novo Nordisk's coramitug CLEOPATTRA trial each have primary completion expected in 2029. Milestone and royalty potential is substantial but contingent on long-duration clinical success. [#SEC-8K-2026-08-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-22 • Updated nightlySource: Internal modelMethodology